>6 months were included; at baseline, 45 were infected with HBV strains with genotypic 55 resistance to lamivudine (LAM) and ETV (the LAM/ETV-R group), 28 to LAM and adefovir 56 (ADV) (the LAM/ADV-R group), and 20 to LAM, ETV, and ADV (the LAM/ETV/ADV-R group). 57 The median duration of rescue therapy was 13.0 (range, 6.7-31.7) months. Seventy-four 58 out of 93 patients (79.6%) achieved complete virologic suppression, after a median 4.5 (95% 59 confidence interval, 3.0-6.0) months. Cumulative probabilities of complete virologic 60 suppression at month 6 were 63.6%: 55.7%, 75.0%, and 65.0% in the LAM/ETV-R, LAM/ADV-61 R, and LAM/ETV/ADV-R groups, respectively. During the treatment period, these 62 probabilities were not significantly different across the resistance profiles before and after 63 IPW (P=0.072 and P=0.510, respectively) . In multivariate analysis, a lower baseline HBV 64 DNA level, but not resistance profiles, was an independent predictor of complete virologic 65 suppression. Renal dysfunction was not observed during the treatment period. In 66 conclusion, rescue therapy with ETV-TDF combination is efficient and safe in patients 67 infected with MDR HBV strains regardless of the antiviral drug resistance profiles.
68

INTRODUCTION
69
The goal of chronic hepatitis B (CHB) treatment is to achieve early and sustained 70 suppression of hepatitis B virus (HBV) replication, which is demonstrated to prevent 71 progression of liver disease to cirrhosis, and development of hepatocellular carcinoma (1, 2).
72
The availability of nucleos(t)ide analogues such as tenofovir disoproxil fumarate (TDF) and groups were balanced using an inverse probability weight for each patient, which was 160 generated based on the propensity score. After IPW, the balance of baseline characteristics 161 among the groups was assessed and thereafter weighted Cox proportional hazards models 162 were fitted. All tests were conducted as two-sided tests and P<0.05 was considered 163 significant. All statistical analyses were performed using SAS software version 9.3 (SAS Inc.,
164
Cary, NC) and PASW statistical software version 18.0 (IBM, Chicago, IL). 165 Lee et al 9
RESULTS
166
Characteristics of the Study Population
167
The baseline clinical and demographic characteristics of the 93 patients are summarized 168 in Table 1 Fig. S1 in the supplemental material).
211
The cumulative probabilities of complete virologic suppression were comparable among Table S1 in the supplemental material).
238
The weighted cumulative probabilities of complete virologic suppression at month 6 were 239 65.9% in the LAM/ETV-R group, 84.6% in the LAM/ADV-R group, and 54.8% in the 240 LAM/ETV/ADV-R group (Fig. 3) that study defined undetectable HBV DNA using a lower limit of 400 copies/mL (60 IU/mL).
285
If that study had used a more sensitive PCR assay, the antiviral efficacy of TDF monotherapy ETV and TDF, is necessary for these difficult-to-treat patients.
292
We acknowledge some limitations resulting from the nature of retrospective study design 293 of this study. Therefore, we aimed to reduce the bias in patient selection and to describe 294 the efficacy of treatment according to the resistance profiles by employment of IPW.
295
Although the weighted probability of complete virologic suppression at month 6 in the Note.-Data in parentheses are 95% CIs.
Lee et al
* P values were determined using Cox proportional hazards regression models. P < 0.05 indicated a significant difference. † Liver cirrhosis was diagnosed when the platelet count was below 100,000/mm 3 and associated splenomegaly or esophageal-gastric varices were detected.
Abbreviations: HBV, hepatitis B virus; ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; LAM, lamivudine; ETV, entecavir; ADV, adefovir
